The Biomedical Prevention Program has 41 investigators from 16 departments and four schools with a research base of $6.8 million in annual direct funding, Including $4.4 million from the NCI. Its members published 1092 papers over this grant period, of which 37% were intra-programmatic and 39% ware interprogrammatic collaborations. 155 of these publications were in high impact journals (Impact factor >7.51). The objective of the Biomedical Prevention Program is to reduce the morbidity and mortality caused by cancer through preventing the occurrence and improving survival with earlier diagnosis. The alms of the program are: 1) To build and to support organ-focused, vertically Integrated research projects that encompass environmental and genetic approaches In order to Identify individuals and populations a high risk for future neoplastic progression;2) To discover and validate biomarkers for risk assessment and early detection of common, high mortality cancers through the integration of high throughput genomic, proteomic, and biotechnologies;3) To Identify and determine preventive efficacy of Interventions with pharmacologic and nutritional tools with the aim of delaying or reversing neoplastic progression in individuals identified at high risk;and 4) To develop and validate new biostatistical methodologies to study population clusters and surrogate endpoints. The populations targeted for these programs include the general population and special at-risk groups.

Public Health Relevance

All of the research in the Biomedical Prevention Program has direct cancer relevance and covers the spectrum of research Including basic pharmacology of chemopreventive agents, gene discovery and risk modeling, proteomic studies that are directly applied to early detection, pharmacologic interventions Including Phase II, investigator initiated trials of chemopreventive agents, pharmacogenetic studies of preventive agents and outcomestudies including biomarkers, survival and prevention of treatment symptoms.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA046592-26
Application #
8696611
Study Section
Subcommittee B - Comprehensiveness (NCI)
Project Start
Project End
Budget Start
2014-06-01
Budget End
2015-05-31
Support Year
26
Fiscal Year
2014
Total Cost
Indirect Cost
Name
University of Michigan Ann Arbor
Department
Type
DUNS #
City
Ann Arbor
State
MI
Country
United States
Zip Code
48109
Holt, Melissa C; Assar, Zahra; Beheshti Zavareh, Reza et al. (2018) Biochemical Characterization and Structure-Based Mutational Analysis Provide Insight into the Binding and Mechanism of Action of Novel Aspartate Aminotransferase Inhibitors. Biochemistry 57:6604-6614
Jiagge, Evelyn; Jibril, Aisha Souleiman; Davis, Melissa et al. (2018) Androgen Receptor and ALDH1 Expression Among Internationally Diverse Patient Populations. J Glob Oncol :1-8
Bowers, Emily; Slaughter, Anastasiya; Frenette, Paul S et al. (2018) Granulocyte-derived TNF? promotes vascular and hematopoietic regeneration in the bone marrow. Nat Med 24:95-102
O'Dwyer, David N; Zhou, Xiaofeng; Wilke, Carol A et al. (2018) Lung Dysbiosis, Inflammation, and Injury in Hematopoietic Cell Transplantation. Am J Respir Crit Care Med 198:1312-1321
Wang, Yin; Day, Mark L; Simeone, Diane M et al. (2018) 3-D Cell Culture System for Studying Invasion and Evaluating Therapeutics in Bladder Cancer. J Vis Exp :
Suresh, Krithika; Owen, Dawn; Bazzi, Latifa et al. (2018) Using Indocyanine Green Extraction to Predict Liver Function After Stereotactic Body Radiation Therapy for Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys 100:131-137
Xiong, Yi; Torsoni, Adriana Souza; Wu, Feihua et al. (2018) Hepatic NF-kB-inducing kinase (NIK) suppresses mouse liver regeneration in acute and chronic liver diseases. Elife 7:
El Kadi, Najwa; Wang, Luo; Davis, April et al. (2018) The EGFR T790M Mutation Is Acquired through AICDA-Mediated Deamination of 5-Methylcytosine following TKI Treatment in Lung Cancer. Cancer Res 78:6728-6735
Feng, Mary; Suresh, Krithika; Schipper, Matthew J et al. (2018) Individualized Adaptive Stereotactic Body Radiotherapy for Liver Tumors in Patients at High Risk for Liver Damage: A Phase 2 Clinical Trial. JAMA Oncol 4:40-47
Thomas, Tina T; Chukkapalli, Sahiti; Van Noord, Raelene A et al. (2018) Utilization of Ultrasound Guided Tissue-directed Cellular Implantation for the Establishment of Biologically Relevant Metastatic Tumor Xenografts. J Vis Exp :

Showing the most recent 10 out of 1493 publications